EEF2K
Eukaryotic elongation factor 2 kinase
Protein Summary
Threonine kinase that regulates protein synthesis by controlling the rate of peptide chain elongation. Upon activation by a variety of upstream kinases including AMPK or TRPM7, phosphorylates the elongation factor EEF2 at a single site, renders it unable to bind ribosomes and thus inactive. In turn, the rate of protein synthesis is reduced. This gene encodes a highly conserved protein kinase in the calmodulin-mediated signaling pathway that links activation of cell surface receptors to cell division. This kinase is involved in the regulation of protein synthesis. It phosphorylates eukaryotic elongation factor 2 (EEF2) and thus inhibits the EEF2 function. The activity of this kinase is increased in many cancers and may be a valid target for anti-cancer treatment. [provided by RefSeq, Jul 2008]
- ENST00000263026
- ENSP00000263026
- ENSG00000103319
- eEF-2K
- CaMKIII
- HSU93850
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
kinase | 1 | ||
transcription factor binding site profile | 0.98 | ||
transcription factor perturbation | 0.88 | ||
ligand (protein) perturbation | 0.83 | ||
hub protein | 0.75 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 65.09 (req: < 5)
Gene RIFs: 65 (req: <= 3)
Antibodies: 403 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 65.09 (req: >= 5)
Gene RIFs: 65 (req: > 3)
Antibodies: 403 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 20
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 1
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0